Atila Tanyeli

Atila Tanyeli

Auto-generated profile, based on publicly available information

Atila Tanyeli

Cukurova University Faculty of Medicine

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
GSGulay Sezgin
Gulay Sezgin
CACan Acipayam
Can Acipayam
AOAyse Ozkan
Ayse Ozkan
IBIbrahim Bayram
Ibrahim Bayram
ATAtila Tanyeli
Atila Tanyeli
Infection is a serious cause of mortality in febrile neutropenia of pediatric cancer patients. Recently, monotherapy has replaced the combination therapy in empirical treatment of febrile neutropenia. Since there has been no reported trial comparing the efficacy of meropenem and piperacillin-tazobactam (PIP/ TAZ) monotherapies, the present retrospective study was conducted to compare safety and efficacy in febrile neutropenic children with cancer. Charts of febrile, neutropenic children hospitalized at our center between March 2008 and April 2011 for hemato-oncological malignancies were reviewed. Patients received PIP/TAZ 360 mg/kg/day or meropenem 60 mg/kg/day intravenously in three divided doses. Duration of fever and neutropenia, absolute neutrophil count, modification, and success rate were compared between the two groups. Resolution of fever without antibiotic change was defined as success and resolution of fever with antibiotic change or death of a patient was defined as failure. Modification was defined as changing the empirical antimicrobial agent during a febrile episode. Two hundred eighty four febrile neutropenic episodes were documented in 136 patients with a median age of 5 years. In 198 episodes meropenem and in 86 episodes PIP/ TAZ were used. Duration of fever and neutropenia, neutrophil count, sex, and primary disease were not different between two groups. Success rates and modification rate between two groups showed no significant differences (p>0.05). Overall success rate in the meropenem and PIP/TAZ groups were 92.4% and 91.9% respectively. No serious adverse effects occurred in either of the groups. Meropenem and PIP/TAZ monotherapy are equally safe and effective in the initial treatment of febrile neutropenia in children with cancer.

19 July 2012 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
SYSema Yilmaz
Sema Yilmaz
NİNihal İNANDIKLIOĞLU
Nihal İNANDIKLIOĞLU
DYDincer Yildizdas
Dincer Yildizdas
CSCansu Subasi
Cansu Subasi
AAArbil Acikalin
Arbil Acikalin
EKErdal Karaoz
Erdal Karaoz

1 January 2010
Verified
Journal Article
Closed access
MKMustafa Kömür
Mustafa Kömür
FEFatih Erbey
Fatih Erbey
IBIbrahim Bayram
Ibrahim Bayram
ATAtila Tanyeli
Atila Tanyeli

30 November 2012 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Closed access
PDF file
NINihal Inandiklioglu
Nihal Inandiklioglu
SYSema Yilmaz
Sema Yilmaz
ODOsman Demirhan
Osman Demirhan
SESeyda Erdogan
Seyda Erdogan
ATAtila Tanyeli
Atila Tanyeli
Neuroblastoma (NB), like most human cancers, is characterized by genomic instability, manifested at the chromosomal level as allelic gain, loss or rearrangement. Genetics methods, as well as conventional and molecular cytogenetics may provide valuable clues for the identification of target loci and successful search for major genes in neuroblastoma. We aimed to investigate AURKA and MYCN gene rearrangements and the chromosomal aberrations (CAs) to determine the prognosis of neuroblastoma. We performed cytogenetic analysis by G-banding in 25 cases [11 girls (44%) and 14 boys (66%)] and in 25 controls. Fluorescence in situ hybridization (FISH) with AURKA and MYCN gene probes was also used on interphase nuclei to screen for alterations. Some 18.4% of patient cells exhibited CAs., with a significant difference between patient and control groups in the frequencies (P<0.0001). Some 72% of the cells had structural aberrations, and only 28% had numerical chnages in patients. Structural aberrations consisted of deletions, translocations, breaks and fragility in various chromosomes, 84% and 52% of the patients having deletions and translocations, respectively. Among these expressed CAs, there was a higher frequency at 1q21, 1q32, 2q21, 2q31, 2p24, 4q31, 9q11, 9q22, 13q14, 14q11.2, 14q24, and 15q22 in patients. 32% of the patients had chromosome breaks, most frequently in chromosomes 1, 2, 3, 4, 5, 8, 9, 11, 12, 19 and X. The number of cells with breaks and the genomic damage frequencies were higher in patients (p<0.001). Aneuploidies in chromosomes X, 22, 3, 17 and 18 were most frequently observed. Numerical chromosome abnormalities were distinctive in 10.7% of sex chromosomes. Fragile sites were observed in 16% of our patients. Our data confirmed that there is a close correlation between amplification of the two genes, amplification of MYCN possibly contributing significantly to the oncogenic properties of AURKA. The high frequencies of chromosomal aberrations and amplifications of AURKA and MYCN genes indicate prognostic value in children with neuroblastomas and may point to contributing factors in their development.

1 May 2014 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
CACan Acipayam
Can Acipayam
SKSerhan Kupeli
Serhan Kupeli
GSGulay Sezgin
Gulay Sezgin
AAArbil Acikalin
Arbil Acikalin
AOAyse Ozkan
Ayse Ozkan
ATAtila Tanyeli
Atila Tanyeli
Here we present a pediatric case of human papilloma virus associated with dermatopathic lymphadenitis (DL). A 5-year-old boy presented to the pediatric oncology clinic with swelling of the neck and warts on his lower jaw. His blood chemistry and complete blood count were normal, as was chest x-ray. HIV, EBV, CMV, and parvovirus serologies were negative. The patient was investigated for malignancy and lymphoma but no association was found. Histopathologic examination of the lymph node and the lesion revealed DL and verruca vulgaris, respectively. DL represents a benign form of reactive lymph node hyperplasia and described in patients with HIV and EBV infections. It is a rare entity described in patients with human papilloma virus infection. To our knowledge, this is the first report of DL in a patient with human papilloma virus infection.

1 January 2010
Verified
Journal Article
Closed access
BKBircan Hizli Karabacak
Bircan Hizli Karabacak
FEFatih Erbey
Fatih Erbey
IBIbrahim Bayram
Ibrahim Bayram
SYSema Yilmaz
Sema Yilmaz
CACan Acıpayam
Can Acıpayam
ATAtila Tanyeli
Atila Tanyeli